Learning to Overcome Barriers While Developing a Breast Oncology Career

News
Video

Tiffany A. Traina, MD, and Sherry Shen, MD, discussed barriers they have had to overcome throughout their oncology careers.

Having proper mentors and overcoming barriers within yourself is something that Tiffany A. Traina, MD, and Sherry Shen, MD, have both learned to climb over throughout their careers. During the Breaking Barriers: Women in Oncology episode, both women in the breast oncology space mentioned how welcomed they have felt by their community, citing few significant disparities in their field.

Traina, vice chair of Outpatient Operations in the Department of Medicine, and section head of the Triple-Negative Breast Cancer Clinical Research Program at Memorial Sloan Kettering Cancer Center (MSKCC), spoke about how she discovered that she needed different mentors in different areas of her life. She feels that this approach helped her become a better clinician, partner, and mother, and led her to where she is today.

Shen, an assistant attending physician at MSKCC, noted that while external barriers haven’t been experienced, she has imparted them upon herself. While it can be intimidating to unearth her voice in a room full of senior colleagues, Shen noted she is finding her way.

Transcript:

Traina:

I was fortunate to have incredible mentors who I think were “gender blind.” It was more about helping to nurture and educate and being excited about introducing the field of oncology to someone. I always felt well supported and recognized that I needed different mentors for different parts of my personal and professional development. There were [mentors] who were incredibly helpful for my academic development. There were colleagues who were incredibly helpful for me to figure out how to juggle life as a physician, a partner, and a mom. I don’t think that I felt barriers ever, I just recognized that it took a tremendous amount of support, and mentorship to get where I am.

Shen:

Fortunately, our field has changed so much, and especially the environment we’re working in here has been so welcoming that I don’t think I felt so much external barriers as perhaps internal barriers. Some of the ways we as women grow up and are raised, I think I have some things that I’ve struggled with, like speaking up in meetings where I felt like my expertise as a junior faculty attending was not at the level where I had a meaningful contribution to make, for example. That’s something I’m working on, internally, and over time [I am] becoming more confident speaking up. Those are the barriers that I’ve encountered.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content